{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,27]],"date-time":"2026-04-27T08:41:30Z","timestamp":1777279290969,"version":"3.51.4"},"reference-count":46,"publisher":"American Society of Clinical Oncology (ASCO)","issue":"11","content-domain":{"domain":["ascopubs.org"],"crossmark-restriction":true},"short-container-title":["JCO Glob Oncol"],"published-print":{"date-parts":[[2025,2]]},"abstract":"<jats:sec>\n            <jats:title>PURPOSE<\/jats:title>\n            <jats:p>\n              We investigated the impact of the funding source (public\n              <jats:italic>v<\/jats:italic>\n              private) on the overall survival (OS) of men with prostate cancer in Brazil.\n            <\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>METHODS<\/jats:title>\n            <jats:p>We retrospectively analyzed patients with prostate cancer from a large hospital registry from the state of S\u00e3o Paulo, Brazil. Patients age 50-99 years diagnosed with prostate acinar adenocarcinoma or adenocarcinoma not otherwise specified (NOS) between January 2014 and December 2017 were eligible. Demographic and clinical features were analyzed alongside the funding source. On the basis of clinical characteristics at diagnosis (lymph node status, distant metastasis, prostate-specific antigen [PSA], and Gleason score), patients were categorized into low-risk, intermediate-risk, high-risk, and metastatic groups.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>RESULTS<\/jats:title>\n            <jats:p>\n              Of 25,009 patients analyzed, 85% had a public funding source. These patients were slightly older, had greater proportion of adenocarcinoma NOS, and higher PSA levels and risk category. There was a significant difference in OS favoring patients with a private funding source (\n              <jats:italic>P<\/jats:italic>\n              &lt; .0001). The estimated OS rates at 5 years were 76.2% (95% CI, 75.6 to 76.9) and 86.9% (95% CI, 85 to 88.7) for the public and private groups, respectively (\n              <jats:italic>P<\/jats:italic>\n              &lt; .0001). The funding source was significantly associated with OS independent of age, educational level, and receipt of any treatment in the intermediate-risk (hazard ratio [HR], 2.28 [95% CI, 1.58 to 3.30];\n              <jats:italic>P<\/jats:italic>\n              &lt; .001) and high-risk (HR, 1.36 [95% CI, 1.02 to 1.80];\n              <jats:italic>P<\/jats:italic>\n              = .04) groups, but not in the low-risk (HR, 0.85 [95% CI, 0.60 to 1.21];\n              <jats:italic>P<\/jats:italic>\n              = .38) or metastatic groups (HR, 0.84 [95% CI, 0.64 to 1.11];\n              <jats:italic>P<\/jats:italic>\n              = .23).\n            <\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>CONCLUSION<\/jats:title>\n            <jats:p>The worse OS observed for patients with prostate cancer with a public source of funding underscores the need for actions directed to improve the standards of public health care in Brazil.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1200\/go-24-00271","type":"journal-article","created":{"date-parts":[[2025,2,6]],"date-time":"2025-02-06T20:59:11Z","timestamp":1738875551000},"update-policy":"https:\/\/doi.org\/10.1200\/crossmark","source":"Crossref","is-referenced-by-count":1,"title":["Impact of Funding Source on Long-Term Outcomes in Prostate Cancer: Analysis of a Large Public Database From Sao Paulo, Brazil"],"prefix":"10.1200","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4288-9018","authenticated-orcid":true,"given":"Fernando C.","family":"Maluf","sequence":"first","affiliation":[{"name":"Hospital Israelita Albert Einstein, S\u00e3o Paulo, Brazil"},{"name":"Hospital Benefic\u00eancia Portuguesa de S\u00e3o Paulo, S\u00e3o Paulo, Brazil"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7385-5729","authenticated-orcid":true,"given":"Cintia S.K.S.","family":"de Oliveira","sequence":"additional","affiliation":[{"name":"Produtos Roche Quimicos e Farmaceuticos, S\u00e3o Paulo, Brazil"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8012-3761","authenticated-orcid":true,"given":"Patr\u00edcia K.","family":"Ziegelmann","sequence":"additional","affiliation":[{"name":"Federal University of Rio Grande do Sul, Porto Alegre, Brazil"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"233","reference":[{"key":"e_1_3_6_2_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(19)31243-7"},{"key":"e_1_3_6_3_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(11)60054-8"},{"key":"e_1_3_6_4_2","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-019-6190-3"},{"key":"e_1_3_6_5_2","unstructured":"Central Inteligence Agency: The World Factbook: Brazil. 2023. https:\/\/www.cia.gov\/the-world-factbook\/countries\/brazil\/"},{"key":"e_1_3_6_6_2","doi-asserted-by":"publisher","DOI":"10.6061\/clinics\/2018\/e430s"},{"key":"e_1_3_6_7_2","doi-asserted-by":"publisher","DOI":"10.1186\/s12889-022-14199-1"},{"key":"e_1_3_6_8_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.lana.2022.100333"},{"key":"e_1_3_6_9_2","doi-asserted-by":"publisher","DOI":"10.1186\/s12913-021-07376-2"},{"key":"e_1_3_6_10_2","unstructured":"Ag\u00eancia Nacional de Sa\u00fade Suplementar: Dados e Indicadores do Setor. 2023. https:\/\/www.gov.br\/ans\/pt-br\/acesso-a-informacao\/perfil-do-setor\/dados-e-indicadores-do-setor"},{"key":"e_1_3_6_11_2","unstructured":"World Health Organization: International Agency for Research on Cancer. Cancer Today. Cancer Fact Sheets. 2023. https:\/\/gco.iarc.fr\/today\/fact-sheets-cancers"},{"key":"e_1_3_6_12_2","volume-title":"Instituto Nacional de C\u00e2ncer. Estimativa 2023: Incid\u00eancia de c\u00e2ncer no Brasil\/Instituto Nacional de C\u00e2ncer","author":"Minist\u00e9rio da Sa\u00fade","year":"2022","unstructured":"Minist\u00e9rio da Sa\u00fade: Instituto Nacional de C\u00e2ncer. Estimativa 2023: Incid\u00eancia de c\u00e2ncer no Brasil\/Instituto Nacional de C\u00e2ncer. Rio de Janeiro, INCA, 2022"},{"key":"e_1_3_6_13_2","doi-asserted-by":"publisher","DOI":"10.1590\/S1677-55382012000200003"},{"key":"e_1_3_6_14_2","doi-asserted-by":"publisher","DOI":"10.1590\/s1518-8787.2017051006766"},{"key":"e_1_3_6_15_2","doi-asserted-by":"publisher","DOI":"10.1007\/s11255-022-03289-z"},{"key":"e_1_3_6_16_2","doi-asserted-by":"publisher","DOI":"10.1158\/1055-9965.EPI-13-0693"},{"key":"e_1_3_6_17_2","doi-asserted-by":"publisher","DOI":"10.1002\/jha2.444"},{"key":"e_1_3_6_18_2","unstructured":"Funda\u00e7\u00e3o Oncocentro S\u00e3o Paulo. https:\/\/fosp.saude.sp.gov.br\/fosp\/diretoria-adjunta-de-informacao-e-epidemiologia\/rhc-registro-hospitalar-de-cancer\/banco-de-dados-do-rhc\/"},{"key":"e_1_3_6_19_2","unstructured":"National Comprehensive Cancer Network: NCCN Clinical Practice Guidelines in Oncology: Prostate Cancer. Version 3.2023"},{"key":"e_1_3_6_20_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1991.9.1.191"},{"key":"e_1_3_6_21_2","doi-asserted-by":"publisher","DOI":"10.1590\/1980-549720210006"},{"key":"e_1_3_6_22_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(17)33326-3"},{"key":"e_1_3_6_23_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(13)62225-4"},{"key":"e_1_3_6_24_2","doi-asserted-by":"publisher","DOI":"10.1002\/cam4.6419"},{"key":"e_1_3_6_25_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2013.02.024"},{"key":"e_1_3_6_26_2","first-page":"e122354","article-title":"Analysis of the time to initiate oncological treatment in Brazil: Demographic and related-to-the-tumor factors","volume":"68","author":"Sobral GS","year":"2022","unstructured":"Sobral GS, Ara\u00fajo YB, Kameo SY, et al: Analysis of the time to initiate oncological treatment in Brazil: Demographic and related-to-the-tumor factors. Rev Bras Cancerol 68:e122354, 2022","journal-title":"Rev Bras Cancerol"},{"key":"e_1_3_6_27_2","doi-asserted-by":"publisher","DOI":"10.1590\/0102-311X00005813"},{"key":"e_1_3_6_28_2","doi-asserted-by":"publisher","DOI":"10.1590\/s1677-5538.ibju.2015.0690"},{"key":"e_1_3_6_29_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.canep.2017.07.016"},{"key":"e_1_3_6_30_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(23)00284-X"},{"key":"e_1_3_6_31_2","doi-asserted-by":"publisher","DOI":"10.1080\/2090598X.2020.1781386"},{"key":"e_1_3_6_32_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMcp2209151"},{"key":"e_1_3_6_33_2","doi-asserted-by":"publisher","DOI":"10.1200\/GO.20.00527"},{"key":"e_1_3_6_34_2","unstructured":"Minist\u00e9rio da Sa\u00fade: C\u00e2ncer de Pr\u00f3stata. 2023. https:\/\/www.gov.br\/saude\/pt-br\/assuntos\/saude-de-a-a-z\/c\/cancer-de-prostata"},{"key":"e_1_3_6_35_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.vhri.2021.02.002"},{"key":"e_1_3_6_36_2","first-page":"e00004119","article-title":"Healthcare trajectories and obstacles faced by women in a health region in Northeast Brazil","volume":"35","author":"Galvao JR","year":"2019","unstructured":"Galvao JR, Almeida PF, Santos AMD, et al: Healthcare trajectories and obstacles faced by women in a health region in Northeast Brazil. Cad Saude Publica 35:e00004119, 2019","journal-title":"Cad Saude Publica"},{"key":"e_1_3_6_37_2","doi-asserted-by":"publisher","DOI":"10.1186\/s12905-020-00995-7"},{"key":"e_1_3_6_38_2","doi-asserted-by":"publisher","DOI":"10.3390\/ijerph17114030"},{"key":"e_1_3_6_39_2","doi-asserted-by":"publisher","DOI":"10.1200\/GO.20.00515"},{"key":"e_1_3_6_40_2","doi-asserted-by":"publisher","DOI":"10.1200\/GO.20.00421"},{"key":"e_1_3_6_41_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijrobp.2018.05.003"},{"key":"e_1_3_6_42_2","doi-asserted-by":"crossref","first-page":"e20223368","DOI":"10.1590\/0100-6991e-20223368-en","article-title":"Surgical capacity assessment in the state of Amazonas using the surgical assessment tool. Cross-sectional study","volume":"49","author":"Souza JE","year":"2022","unstructured":"Souza JE, Ferreirai RV, Saluja S, et al: Surgical capacity assessment in the state of Amazonas using the surgical assessment tool. Cross-sectional study. Rev Col Bras Cir 49:e20223368, 2022","journal-title":"Rev Col Bras Cir"},{"key":"e_1_3_6_43_2","first-page":"100506","article-title":"Marketing authorisation and pricing of FDA-approved cancer drugs in Brazil: A retrospective analysis","volume":"22","author":"Ivama-Brummell AM","year":"2023","unstructured":"Ivama-Brummell AM, Marciniuk FL, Wagner AK, et al: Marketing authorisation and pricing of FDA-approved cancer drugs in Brazil: A retrospective analysis. Lancet Reg Health Am 22:100506, 2023","journal-title":"Lancet Reg Health Am"},{"key":"e_1_3_6_44_2","doi-asserted-by":"publisher","DOI":"10.1200\/GO.20.00505"},{"key":"e_1_3_6_45_2","doi-asserted-by":"publisher","DOI":"10.1200\/GO.20.00511"},{"key":"e_1_3_6_46_2","doi-asserted-by":"publisher","DOI":"10.1590\/0102-311xen130222"},{"key":"e_1_3_6_47_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(16)30171-1"}],"container-title":["JCO Global Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ascopubs.org\/doi\/pdfdirect\/10.1200\/GO-24-00271","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,6]],"date-time":"2025-02-06T20:59:31Z","timestamp":1738875571000},"score":1,"resource":{"primary":{"URL":"https:\/\/ascopubs.org\/doi\/10.1200\/GO-24-00271"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2]]},"references-count":46,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2025,2]]}},"alternative-id":["10.1200\/GO-24-00271"],"URL":"https:\/\/doi.org\/10.1200\/go-24-00271","relation":{},"ISSN":["2687-8941"],"issn-type":[{"value":"2687-8941","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,2]]},"assertion":[{"value":"2024-06-12","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-11-18","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-12-13","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-02-06","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e2400271"}}